^
    1m
    Clinical Performance of tissue- and plasma-based diagnostic assays in identifying homologous recombination repair gene alterations in patients with metastatic castration-resistant prostate cancer following the treatment with niraparib with abiraterone acetate and plus Prednisone (Niraparib + AAP). (PubMed, J Mol Diagn)
    Clinically meaningful benefits for all endpoints were comparable for BRCA+ and HRR+ patients detected by either tissue or plasma assays. These results demonstrated the clinical utility of both tissue and plasma assays in identifying patients for NIRA+AAP treatment.
    Journal • Diagnostic assay • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    FoundationOne® CDx • Resolution HRD assay
    |
    Zejula (niraparib) • abiraterone acetate • prednisone